Sparsentan is a pharmaceutical raw material that functions as a dual endothelin and angiotensin receptor antagonist. It is studied for its potential role in conditions such as primary immunoglobulin A nephropathy and focal segmental glomerulosclerosis.
Content scope: Information here supports chemical identification and industrial supply, research, and manufacturing contexts. It is not a therapeutic claim, medical advice, or drug-use instructions.
Sourcing or supplying this compound?
List your inventory or post a purchase request
CAS 254740-64-2
4'-((2-Butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-N-(4,5-dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-N-(methoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
pharmaceutical intermediate
Isoquinolin-3-amine
pharmaceutical raw material
Lirafugratinib
pharmaceutical raw material
Clindamycin palmitate hydrochloride
pharmaceutical raw material
Alovudine
pharmaceutical raw material
2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-N-(4,5-dimethyl-1,2-oxazol-3-yl)benzenesulfonamide
WRFHGDPIDHPWIQ-UHFFFAOYSA-N
CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC(=C(C=C3)C4=CC=CC=C4S(=O)(=O)NC5=NOC(=C5C)C)COCC